Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells

BACKGROUND: Aberrant expression and activation of the IGF-IR have been reported in a variety of human cancers and have been associated with resistance to HER targeted therapy. In this study, we investigated the effect of simultaneous targeting of IGF-IR and HER (erbB) family, with NVP-AEW541 and afa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ioannou, Nikolaos, Seddon, Alan M, Dalgleish, Angus, Mackintosh, David, Modjtahedi, Helmout
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598209/
https://www.ncbi.nlm.nih.gov/pubmed/23367880
http://dx.doi.org/10.1186/1471-2407-13-41

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598209/
https://www.ncbi.nlm.nih.gov/pubmed/23367880
http://dx.doi.org/10.1186/1471-2407-13-41

Ejemplares similares